Management Team

William McVicar, Ph.D., is a pharmaceutical executive with approximately 30 years of clinical development experience. He joined Flex Pharma in April 2017 as President of Research & Development and was appointed CEO in July 2017. Before that, he served as Executive Vice President of Pharmaceutical Development, Chief Scientific Officer and President at Inotek. As Vice President of Development Operations at Sepracor, he oversaw the development, FDA review and approval of multiple NDAs and sNDAs, including BROVANA®, XOPENEX MDI® and XOPENEX’s pediatric approval, each approved in a single 10-month review cycle. Earlier, he held positions of increasing responsibility at Sandoz, Novartis and Rhone Poulenc Rorer.

Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont. He led Flex Pharma through its 2019 merger with Salarius Pharmaceuticals and currently serves as Chairman of the Board of Directors of Decoy Therapeutics.

John McCabe is a biopharma finance executive. He joined Flex Pharma in 2014 as Vice President, Finance, and became Chief Financial Officer in December 2016. He came from ARIAD Pharmaceuticals, where he was Vice President and Chief Accounting Officer. Previously, he served as Vice President and Corporate Controller at Charles River Associates, where he was responsible for all aspects of global financial accounting, planning and reporting. Before that, he was Director and strategic business unit Controller at Biogen Idec, managing all accounting and government pricing functions for the U.S. commercial business, including Avonex, Tysabri and Rituxan. Mr. McCabe started his career at Arthur Andersen & Co., where he advanced to Audit Manager, and later held financial positions at two technology companies.

Mr. McCabe holds B.S. degrees in accounting and management information systems from Babson College and an M.B.A. from the University of Massachusetts at Amherst. After Flex Pharma he was Chief Financial Officer of Oncorus, and he now works with Longwood Fund as Portfolio Company CFO & COO, including as CFO of Longwood-founded Newleos Therapeutics.